AGIO Agios Pharmaceuticals Inc.

53.35
+0.79  (+2%)
Previous Close 52.56
Open 52.58
Price To Book 8.13
Market Cap 3,647,568,522
Shares 68,370,544
Volume 152,732
Short Ratio
Av. Daily Volume 861,121
Stock charts supplied by TradingView

NewsSee all news

  1. TIO Bioventures Expands and Strengthens Team with the Appointment of Industry Veteran Rachel W. Humphrey, M.D., as Head of R&D at TIO Discovery

    Dr. Humphrey will oversee and drive clinical development efforts in TIO Bioventures' oncology-focused portfolio companies TIO Bioventures, an emerging life science venture creation fund with a mission to build

  2. TIO Bioventures Launches Treadwell Therapeutics, Seeded With $27m to Develop First-in-Class Oral Medicines Against Novel Targets

    Industry Veteran Rachel W. Humphrey, M.D., Head of R&D at TIO Discovery, appointed as Board Member and Chief Medical Officer of Treadwell Therapeutics TIO Bioventures, an emerging life science venture creation fund

  3. Agios Announces "Agios 2025" Strategic Vision and Highlights 2020 Milestones

    – In 2025, Company Expects to Have 4 Marketed Products in at Least 8 Indications, at Least 6 Molecules in Clinical Development and a Broad Research Pipeline – – Broadening Opportunities for PKR Activation: Topline Data

  4. Agios to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020

    CAMBRIDGE, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is

  5. Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation

    CAMBRIDGE, Mass., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 updated data due at EHA June 11 - 14, 2020.
AG-348 - Mitapivat
Thalassemia
FDA Approval announced July 20, 2018.
Ivosidenib
IDH1m Relapsed/Refractory AML - cancer
Phase 3 enrolment to be completed 2019.
AG-348 (ACTIVATE)
Pyruvate kinase deficiency
Phase 3 enrolment to be completed 2020.
AG-120 and VIDAZA - AGILE
Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
Approval announced August 1, 2017.
IDHIFA (enasidenib) - AG-221
Advanced hematologic malignancies with an IDH2 mutation
sNDA filing due to be filed following final overall survival analysis mid-2020.
AG-120 Ivosidenib (ClarIDHy)
IDH1 mutant positive cholangiocarcinoma - cancer
Phase 1 data at ASCO June 2018 noted CR rate was 24%.
AG-120 Ivosidenib
R/R Acute Myeloid Leukemia (AML)
Phase 1 updated data February 25, 2019 noted ORR of 78%, 57% CR rate, and 12-month Survival Rate of 82%.
Enasidenib or ivosidenib with VIDAZA
Frontline AML with IDH1 or IDH2 mutation
Phase 1 updated data at ASH December 2018. CR+CRi/CRp 80%.
Ivosidenib or enasidenib
Frontline AML with IDH1 or IDH2 mutation
Phase 1 data presented at AACR-NCI-EORTC October 27, 2019. Trial is ongoing.
AG-270
Solid tumors
Phase 3 trial to be initiated YE 2019.
Vorasidenib (AG-881)
Glioma
FDA Approval announced May 2, 2019.
Ivosidenib
Frontline AML with IDH1 mutation
Phase 1 updated data noted 31% ORR with postoperative treatment - November 22, 2019.
Ivosidenib and Vorasidenib (AG-881)
IDHm low-grade glioma
Phase 1 updated data at ASCO June 3, 2019. 30% CR rate.
Ivosidenib
IDH1 mutant newly diagnosed AML ineligible for standard therapies
Phase 1 updated data at ASH December 9, 2019 noted complete response (CR) rate of 61% and a CR + CR with partial hematologic recovery (CRh) rate of 70%.
Ivosidenib and azacitidine ( Vidaza)
Newly diagnosed AML with an IDH1 mutation
Phase 3 data due by the end of 2020.
AG-348 - Mitapivat (ACTIVATE)
Pyruvate Kinase Deficiency
Phase 1 data due mid-2020.
AG-348 - Mitapivat
Sickle cell disease.

Latest News

  1. TIO Bioventures Expands and Strengthens Team with the Appointment of Industry Veteran Rachel W. Humphrey, M.D., as Head of R&D at TIO Discovery

    Dr. Humphrey will oversee and drive clinical development efforts in TIO Bioventures' oncology-focused portfolio companies TIO Bioventures, an emerging life science venture creation fund with a mission to build

  2. TIO Bioventures Launches Treadwell Therapeutics, Seeded With $27m to Develop First-in-Class Oral Medicines Against Novel Targets

    Industry Veteran Rachel W. Humphrey, M.D., Head of R&D at TIO Discovery, appointed as Board Member and Chief Medical Officer of Treadwell Therapeutics TIO Bioventures, an emerging life science venture creation fund

  3. Agios Announces "Agios 2025" Strategic Vision and Highlights 2020 Milestones

    – In 2025, Company Expects to Have 4 Marketed Products in at Least 8 Indications, at Least 6 Molecules in Clinical Development and a Broad Research Pipeline – – Broadening Opportunities for PKR Activation: Topline Data

  4. Agios to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020

    CAMBRIDGE, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is

  5. Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation

    CAMBRIDGE, Mass., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food

  6. Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency

    – Robust Hemoglobin Increases Maintained in 18 Patients in the Extension Phase of the Study with Median Treatment Duration of Three Years – – Cumulative Safety Profile (Core Period plus Extension Phase) Continues to

  7. Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)

    – Combination Therapy with TIBSOVO® and Azacitidine Results in Deep and Durable Molecular Remission in Newly Diagnosed IDH1 Mutant AML – – Mechanisms of Resistance and Relapse to Single Agent IDH1 Inhibitors Are Complex

  8. Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results

    – Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 7 of 8 Evaluable Patients – – Safety Profile Consistent with Previously Published Phase 2 Data for Mitapivat in Patients with Pyruvate Kinase

  9. Agios Appoints Bruce Car, Ph.D., as Chief Scientific Officer

    CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment of

  10. Agios Appoints Jonathan Biller as Chief Legal Officer

    CAMBRIDGE, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment of

  11. Agios Presents New Pharmacodynamic and Response Data from Both Cohorts of the Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib) in Patients with IDH1 Mutant Positive Low-Grade Glioma

    – Preliminary Efficacy Data Show 31% Overall Response Rate for Both Vorasidenib and TIBSOVO® with Postoperative Treatment – – Vorasidenib and TIBSOVO® Showed 2-HG Suppression of Greater Than 90% in Resected IDH1 Mutant

  12. CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib

    SUZHOU, China, Nov. 19, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the first patient has been dosed in the Phase I bridging registrational

  13. Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

    CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise

  14. Agios Announces Pricing of $256 Million Public Offering of Common Stock

    CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that it has priced an underwritten public offering of 8,250,000 shares of common stock at a price to the

  15. Agios Announces Proposed Offering of Common Stock

    CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to 7.5 million shares of its common

  16. Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the 2019 ASH Annual Meeting

    – Important Translational Data for TIBSOVO® Underscore the High Clinical and Molecular Remissions Rate Observed in Combination with Azacitidine in IDH1 Mutant AML and Expand Understanding of Resistance Mechanisms – –

  17. Agios Reports Business Highlights and Third Quarter 2019 Financial Results

    – TIBSOVO® Net Revenue of $17.4 Million; 27% Growth from Q2 2019 – – Reported Positive Phase 3 ClarIDHy Results for TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma; sNDA Submission Planned by Year-End – –

  18. Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors

    – Plasma SAM Biomarker Indicates Robust Target Engagement at Well Tolerated Doses; AG-270 Maximum Tolerated Dose Determined to be 200 mg Once Daily – – Combination Arms of Phase 1 Study Evaluating AG-270 in Combination

  19. Agios to Webcast Conference Call of Third Quarter 2019 Financial Results on October 31, 2019

    CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company

  20. Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International Conference

    CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that results from the

  21. Data from Agios' Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients

    – TIBSOVO® Reduced the Risk of Disease Progression or Death by 63% (HR=0.37, p<0.001); Median PFS for Patients Randomized to TIBSOVO® was 2.7 months Compared to 1.4 Months with Placebo – – TIBSOVO® Patients Had

  22. Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO

    CAMBRIDGE, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that results from the

  23. Agios Announces Publication of Data for Mitapivat from Core and Extension Phases of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency in the New England Journal of Medicine

    –  Maximum Hemoglobin Increases >1.0 g/dL Observed in 50% of Patients in Core Period, Among Whom the Mean Maximum Hemoglobin Increase was 3.4 g/dL – – Hemoglobin Responses Maintained in 19 Patients in the Extension

  24. Agios to Present at the Citi 14th Annual Biotech Conference on Thursday, September 5, 2019

    CAMBRIDGE, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is